Form 4: Lexeo Therapeutics Director Acquires 36,000 Stock Options

Tolga Tanguler, a director at Lexeo Therapeutics, acquired 36,000 stock options on November 11, 2024, at an exercise price of $7.95.

Summary

• Tolga Tanguler, a director of Lexeo Therapeutics, acquired 36,000 stock options on November 11, 2024.
• The exercise price for these options is $7.95 per share.
• The options vest in equal annual installments over three years, becoming fully vested on the third anniversary of the grant date, contingent on continuous service.
• The options expire on November 10, 2034.

Sentiment

Score: 5

Explanation: The document is a routine filing related to stock option grants, which is neither positive nor negative in itself. It is a neutral event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of three years is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price is set at a specific value, which is common for stock options.

Stakeholder Impact

• The stock option grant could potentially increase the director's alignment with shareholder interests.

Key Dates

Keywords

stock options, director, insider trading, equity, Lexeo Therapeutics, LXEO, vesting